Is AbbVie Stock a Buy?

With its shares offering a total return of nearly 49% over the last three years, trumping the market's return of 33%, AbbVie (NYSE: ABBV) is a powerhouse big pharma that has a lot of upside to offer to investors.While there's no guarantee the next three years of the company's life will outperform the market, there's a solid thesis for why it's not improbable. Here's what you need to know about this stock to decide whether you want to own it.AbbVie is notable among the major pharma businesses for its smooth execution of its carefully planned pipeline strategy. Assuming that reputation holds up, it's a significant reason to think about buying the stock.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool